Data-gathering tools face a number of challenges including the integration of UDIs, differing device systems and components, and obtaining sufficient follow-up information, and capturing differences in provider experiences and training that could skew the outcomes data.
Quintiles, the world's largest CRO, is rolling toward its biggest year yet on the heels of a fourth straight quarter with more than $1 billion in sales.
MonoSol Rx announced that the U.S. Patent and Trademark Office will decide by August 2015 whether BioDelivery Sciences International's BEMA drug delivery technology infringes on a patent protecting its Suboxone sublingual film.
Quintiles, the world's largest CRO, is dialing up its focus on nascent drugmakers, launching a biotech-focused service offering designed to meet the particular needs of the industry's seedlings without losing them in the Big Pharma shuffle.
Global CRO Quintiles and gene sequencing magnate Illumina are scouting for some promising scientists, offering the use of their cash and technology to advance oncology research.
Quintiles has signed a deal with a Roche diagnostics subsidiary to offer cancer screenings in China, looking to capitalize on the growing market for clinical trials in the country.
Ventana and Quintiles are partnering up to provide companion diagnostic testing services in China for early clinical trials. China is among a few countries that requires patient samples used in clinical trials to be tested domestically for inclusion in the country's approval process.
Quintiles hit the $1 billion revenue mark for a third straight quarter, dialing up its full-year guidance as it expands its share of the global outsourcing market.
Basilea Pharmaceutica ran into an FDA roadblock in its efforts to commercialize a new antibiotic, but the Swiss drug developer already has a green light in Europe, and it's tapping Quintiles' global marketing expertise to launch the treatment on its home continent.
Quintiles has wrapped up its acquisition of healthcare analytics provider Encore, part of the CRO's push to grow its post-market services.